Interestingly, only tumor-bearing mS100a7a15-overexpressing bi-transgenic mice responded to cPLA2 inhibitor and showed reduced recruitment of MDSCs both in spleen and tumors (Fig. 5A-F). Here, PLA2G4A is linked to neoplasm.